Q4 and Full Year 2023 Financial Results Appendix



Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	 Three Months Ended December 31,				Twelve Months Ended December 31,			
	2023		2022		2023		2022	
Reconciliation of GAAP to Non-GAAP research and development:								
GAAP Research and development	\$ 272,141	\$	262,039	\$	1,004,415	\$	883,015	
Less: Stock-based compensation expenses	 (19,085)		(16,944)		(97,273)		(92,161)	
Non-GAAP Research and development	\$ 253,056	\$	245,095	\$	907,142	\$	790,854	
Reconciliation of GAAP to Non-GAAP selling, general and administrative:								
GAAP Selling, general and administrative	\$ 198,123	\$	210,344	\$	795,646	\$	770,658	
Less: Stock-based compensation expenses	 (22,909)		(25,823)		(124,407)		(138,488)	
Non-GAAP Selling, general and administrative	\$ 175,214	\$	184,521	\$	671,239	\$	632,170	
Reconciliation of GAAP to Non-GAAP operating loss:								
GAAP operating loss	\$ (116,404)	\$	(188,614)	\$	(282,175)	\$	(785,072	
Add: Stock-based compensation expenses	 41,994		42,767		221,680		230,649	
Non-GAAP Operating loss	\$ (74,410)	\$	(145,847)	\$	(60,495)	\$	(554,423	



Alnylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

	December 31, 2023		
	Three Months Ended	Twelve Months Ended	
Total TTR net product revenue growth, as reported	33 %	40 %	
Add: Impact of foreign currency translation	(2)		
Total TTR net product revenue growth at constant currency	31 %	40 %	
Total Ultra Rare net product revenue growth, as reported	30 %	35 %	
Add: Impact of foreign currency translation	(3)		
Total Ultra Rare net product revenue growth at constant currency	27 %	35 %	
Total net product revenue growth, as reported	32 %	39 %	
Add: Impact of foreign currency translation	(2)		
Total net product revenue growth at constant currency	30 %	39 %	
Total revenue growth, as reported	31 %	76 %	
Add: Impact of foreign currency translation	(2)		
Total revenue growth at constant currency	29 %	76 %	



34